디아민 유도체의 산부가염 및 이의 제조 방법
    2.
    发明申请
    디아민 유도체의 산부가염 및 이의 제조 방법 审中-公开
    二胺衍生物的酸加成盐及其制备方法

    公开(公告)号:WO2018038426A1

    公开(公告)日:2018-03-01

    申请号:PCT/KR2017/008576

    申请日:2017-08-08

    CPC classification number: C07C269/06 C07C269/08 C07C271/24

    Abstract: 본 발명은 광학 활성 디아민 유도체의 신규한 산부가염 및 이의 제조 방법에 관한 것이다. 본 발명의 디아민 유도체의 산부가염은 에독사반을 고순도 및 고수율로 제조할 수 있고, 독성 문제가 없으며, 비교적 간단한 공정 및 저렴한 비용으로 제조할 수 있는 제조 방법을 제공하여, 비용 및/또는 시간 면에서 경제적으로, 대량 생산에 유리하여 산업화에 사용될 수 있다.

    Abstract translation: 本发明涉及光学活性二胺衍生物的新型酸加成盐及其制备方法。 本发明的二胺衍生物的酸加成盐可以提供一种制备方法,该方法能够以高纯度和高收率生产环氧化剂,无毒性问题,并且可以以相对简单的工艺和低成本制造, 它可用于工业化,因为它在批量生产方面具有经济优势。

    쥐꼬리망초 추출물을 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물
    3.
    发明申请
    쥐꼬리망초 추출물을 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물 审中-公开
    用于预防或治疗呼吸疾病的药物组合物,

    公开(公告)号:WO2017179931A1

    公开(公告)日:2017-10-19

    申请号:PCT/KR2017/004033

    申请日:2017-04-13

    Abstract: 본 발명은 쥐꼬리망초( Justicia procumbens L . ) 알코올 또는 유기용매 추출물을 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물, 및 저스티시딘 A (Justicidin A), 저스티시딘 B (Justicidin B), 저스티시딘 C (Justicidin C) 및 필라미리신 C (Phyllamyricin C) 중 어느 하나 이상을 포함하는 쥐꼬리망초( Justicia procumbens L . ) 알코올 또는 유기용매 추출물을 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물, 및 이들의 호흡기 질환 예방 또는 개선용 식품 조성물에 관한 것이다. 본 발명의 쥐꼬리망초 추출물을 포함하는 조성물은 비장세포의 비정상적인 과증식을 억제하고 알레르기 염증성 사이토카인의 분비를 억제할 수 있으며, 객담 배출 효과 및 기도 수축 억제효과를 나타내므로, 호흡기 질환을 효과적으로 예방, 치료 또는 개선할 수 있다.

    Abstract translation:

    本发明jwikkori芒硝(爵床的→ )预防或治疗呼吸疾病,包括醇或有机溶剂提取物作为活性成分的 包含药物组合物和包含Justicidin A,Justicidin B,Justicidin C和Phyllamyricin C中的一种或多种的大鼠尾胚的药物组合物, (爵床的→ 的)醇或有机溶剂提取物呼吸预防或治疗疾病,包括药物组合物,以及它们的呼吸系统疾病的预防或食品组合物用于改善 Lt。 组合物,包含本发明的jwikkori芒硝提取物表现出的脾细胞的抑制异常增生和可能抑制过敏性炎性细胞因子,痰放电效应及气道收缩抑制效果的释放,有效地防止,治疗呼吸系统疾病 或者可以改进。

    개선된 자보플록사신의 제조방법

    公开(公告)号:KR102213991B1

    公开(公告)日:2021-02-09

    申请号:KR1020140060112

    申请日:2014-05-20

    Abstract: 본발명은자보플록사신 D-아스파르트산염의개선된제조방법에관한것이다. 본발명은자보플록사신 D-아스파르트산염을제조하기위하여사용하는출발물질인 8-메톡시이미노-2,6-디아자-스피로[3,4]옥탄-2-카르복실산 t-부틸에스테르숙신산염(TBDCS) 또는 2-(2,2,2-트리플루오로-아세틸)-2,6-디아자-스피로[3.4]옥탄-8-온 O-메틸옥심메탄설폰산염(TDMOS)의신규한제조방법을제공한다. 본발명에따른제조방법은상기출발물질을높은수율과높은품질(HPLC 순도; 99.5% 이상)로제조할수 있어, 대량생산에적합하며, 치환반응시 TBDCS나 TDMOS를 1.0~1.1 당량을사용하여획기적으로생산단가를절감할수 방법을제공하기때문에자보플록사신 D-아스파르트산염의대량생산에유용하게이용될수 있다.

    광학활성을 유발하는 7-피롤리딘 치환체를 갖는광학활성의 퀴놀린 카르복실산 유도체 및 그의 제조방법
    5.
    发明公开
    광학활성을 유발하는 7-피롤리딘 치환체를 갖는광학활성의 퀴놀린 카르복실산 유도체 및 그의 제조방법 无效
    具有诱导光学活性的7-吡咯烷酮取代基的光学活性喹啉羧酸衍生物及其制备方法

    公开(公告)号:KR1020010029698A

    公开(公告)日:2001-04-06

    申请号:KR1020000024657

    申请日:2000-05-09

    Abstract: PURPOSE: Provided is a method for manufacturing 4-aminomethyl-4-methyl-3-(Z)-alkoxyamino derivative which has antibacterial effects on both gram positive and negative bacteria so that the derivative is useful for medical purposes. And Its pharmaceutically acceptable salt and its solvate are also provided. CONSTITUTION: A method for producing 4-aminomethyl-4-methyl-3-(Z)-alkoxyamino derivative comprises the following steps of: i) reacting the compound of the formula (3) with ketal compound of the formula (2a) in the presence of acid receptor, for 1-24 hours at 0-150 deg.C, preferably from room temperature to 90 deg.C, to manufacture optically active quinoline carboxylic acid derivative of the formula (4); ii) deketalizing the quinoline carboxylic acid derivative to manufacture pyrrolidinone of the formula (5) at from room temperature to 100 deg.C; and iii) reacting the pyrrolidinone with alkoxylamine in the presence of base at 0-90 deg.C. In the formula (1), Q is C-H, C-F, C-CL, or N. Y is H or NH2. R is a C1-C4 linear or branched alkyl, aryl, or benzyl group. * is an optically pure asymmetric carbon.

    Abstract translation: 目的:提供对革兰氏阳性细菌和阴性细菌都具有抗菌作用的4-氨基甲基-4-甲基-3-(Z) - 烷氧基氨基衍生物的制备方法,因此该衍生物可用于医疗目的。 还提供其药学上可接受的盐及其溶剂合物。 构成:4-氨基甲基-4-甲基-3-(Z) - 烷氧基氨基衍生物的制备方法包括以下步骤:i)使式(3)的化合物与式(2a)的缩酮化合物反应于 存在酸受体,在0-150℃,优选室温至90℃下进行1-24小时,以制备式(4)的光学活性喹啉羧酸衍生物; ii)将喹啉羧酸衍生物缩酮化,制备式(5)的吡咯烷酮,室温至100℃; 和iii)在0-90℃下,在碱的存在下使吡咯烷酮与烷氧基胺反应。 在式(1)中,Q是C-H,C-F,C-CL或N.Y是H或NH 2。 R是C1-C4直链或支链烷基,芳基或苄基。 *是光学纯的不对称碳。

    신규한디아릴설포닐이미다졸론유도체

    公开(公告)号:KR100438482B1

    公开(公告)日:2004-08-18

    申请号:KR1019960051939

    申请日:1996-11-05

    Abstract: PURPOSE: Diarylsulfonyl imidazolone derivative and a preparation method thereof are provided. The derivative has improved anticancer activity and do not form aniline derivative causing side-effects. CONSTITUTION: The 4-phenyl-1-(N-carbamoylindoline-5-sulfonyl)- 4,5-dihydro-2-imidazolone derivative is represented by the formula (I), wherein X is oxygen or sulfur; R is C1-C6 alkyl, chloroacetyl, benzyl, phenyl, methoxyphenyl, fluorophenyl, methylphenyl, aminophenyl or thiomethylphenyl; and R' is hydrogen or chlorine. An anticancer pharmaceutical composition comprises the diarylsulfonyl imidazolone derivative of the formula (I) and pharmaceutically acceptable salts thereof as effective components. The method for preparing the 4-phenyl-1-(N-carbamoylindoline-5-sulfonyl)- 4,5-dihydro-2-imidazolone derivative represented by the formula (I) comprises reacting a compound of the formula (II) with a compound of the formula (III).

    플루오로피롤리딘 치환체를 포함하는 퀴놀린 카르복실산유도체 및 그의 제조방법
    9.
    发明公开
    플루오로피롤리딘 치환체를 포함하는 퀴놀린 카르복실산유도체 및 그의 제조방법 无效
    喹啉羧酸衍生物与氟代吡咯烷酮取代物及其制备方法

    公开(公告)号:KR1020030081762A

    公开(公告)日:2003-10-22

    申请号:KR1020020020136

    申请日:2002-04-12

    CPC classification number: Y02P20/55

    Abstract: PURPOSE: A quinoline carboxylic acid derivative with fluoropyrrolidine substituents and a preparation process thereof are provided. The compound has no toxicity and improved antimicrobial activity to both gram positive and negative bacteria. CONSTITUTION: A quinoline carboxylic acid derivative represented by the formula 1 in which 4-aminomethyl-4-fluoro-3-(Z)-alkoxyiminopyrrolidine is substituted at the 7-site of the quinolone scaffold, pharmaceutically acceptable acid adding salt and solvates thereof are provided. In the formula, Q is C-H, C-F, C-Cl, C-OCH3, C-OCHF2, C-CH3 or N; R is hydrogen, methyl or NH2; R1 is ethyl, cyclopropyl, t-butyl, or at least one fluoro substituted phenyl; R2 is hydrogen, C1-C5 alkyl, cyclopropyl, cyclopropyl methyl, C3-C6 alkenyl, C3-C6 alkynyl, phenyl or benzyl; and R3 or R4 is independently hydrogen, or C1-C3 alkyl, or R3 or R4 is hydrogen or C1-C3 alkyl bound nitrogen containing C3-C5 hetero ring compound. A process for preparing the quinoline carboxylic acid derivative represented by the formula 1 comprises the steps of: (1) reacting a quinolone scaffold compound of the formula 2 with a fluoro containing compound of the formula 3 in the presence of a solvent and a base to prepare a compound of the formula 4; and (2) deprotecting the compound of formula 4 with HX, wherein R3 or R4 is hydrogen; P is hydrogen or amine-protecting group; and X is F or Cl.

    Abstract translation: 目的:提供具有氟吡咯烷取代基的喹啉羧酸衍生物及其制备方法。 该化合物对革兰氏阳性菌和阴性菌均无毒性和改善的抗微生物活性。 构成:在喹诺酮支架的7-位取代有4-氨基甲基-4-氟-3-(Z) - 烷氧基亚氨基吡咯烷的式1所示的喹啉羧酸衍生物,其药学上可接受的酸加成盐及其溶剂合物是 提供。 在该式中,Q为C-H,C-F,C-Cl,C-OCH 3,C-OCHF 2,C-CH 3或N; R是氢,甲基或NH 2; R 1是乙基,环丙基,叔丁基或至少一个氟取代的苯基; R 2是氢,C 1 -C 5烷基,环丙基,环丙基甲基,C 3 -C 6烯基,C 3 -C 6炔基,苯基或苄基; 并且R 3或R 4独立地是氢或C 1 -C 3烷基,或者R 3或R 4是氢或C 1 -C 3烷基键合的含有C 3 -C 5杂环化合物的氮。 制备由式1表示的喹啉羧酸衍生物的方法包括以下步骤:(1)在溶剂和碱的存在下使式2的喹诺酮支架化合物与式3的含氟化合物反应, 制备式4的化合物; 和(2)用HX使式4的化合物脱保护,其中R3或R4是氢; P是氢或胺保护基; X为F或Cl。

    광학활성을 유발하는 7-피롤리딘 치환체를 갖는 광학활성의 퀴놀린 카르복실산 유도체 및 그의 제조방법
    10.
    发明公开
    광학활성을 유발하는 7-피롤리딘 치환체를 갖는 광학활성의 퀴놀린 카르복실산 유도체 및 그의 제조방법 有权
    具有导致光学活性的7-吡咯烷酮替代物的光学活性喹啉羧酸衍生物及其制备方法

    公开(公告)号:KR1020020002461A

    公开(公告)日:2002-01-09

    申请号:KR1020017014647

    申请日:2000-05-18

    CPC classification number: C07D401/04 C07D471/04 C07D487/10

    Abstract: PURPOSE: Provided are optically active quinoline carboxylic acid derivatives, pharmaceutically acceptable salts thereof, solvates thereof, and a process for preparation thereof, which are useful for an antibacterial agent. CONSTITUTION: The optically active quinoline carboxylic acid derivatives are represented by the following formula(1), and contains optical activity-causing 4-aminomethyl-4-methyl-3 (Z)-alkoxyiminopyrrolidine substituents at the 7-position of the quinolone nuclei, their pharmaceutically acceptable salts, and their solvates. In the formula(1), Q is C-H, C-F, C-Cl or N; Y is H or NH2; R is a straight or branched alkyl group of Cl-C, an allyl group or a benzyl group, and * represents optically pure chiral carbon atom. Their preparation process comprises the steps of: condensing the quinolone nuclei-containing compound of formula(3), with the ketal compound of formula(2a), in the presence of an acid acceptor to give the optically active quinoline carboxylic acid derivative of formula(4); deketalizing the optically active quinoline carboxylic acid derivative of formula(4) to give the pyrrolidinone compound of formula(5); and reacting the pyrrolidinone compound of formula(5) with an alkoxylamine in the presence of a base to obtain the desired compound of formula(1).

    Abstract translation: 目的:提供可用于抗菌剂的光学活性喹啉羧酸衍生物,其药学上可接受的盐,溶剂合物及其制备方法。 构成:光学活性喹啉羧酸衍生物由下式(1)表示,并且在喹诺酮核的7-位含有光学活性的4-氨基甲基-4-甲基-3(Z) - 烷氧基亚氨基吡咯烷取代基, 其药学上可接受的盐及其溶剂合物。 在式(1)中,Q是C-H,C-F,C-Cl或N; Y为H或NH 2; R是Cl-C,烯丙基或苄基的直链或支链烷基,*表示光学上纯的手性碳原子。 它们的制备方法包括以下步骤:在酸受体存在下将式(3)的喹诺酮核含有化合物与式(2a)的缩酮化合物缩合,得到式(3)的光学活性喹啉羧酸衍生物 4); 对式(4)的光学活性喹啉羧酸衍生物进行缩酮化,得到式(5)的吡咯烷酮化合物; 并在碱的存在下使式(5)的吡咯烷酮化合物与烷氧基胺反应,得到所需的式(1)化合物。

Patent Agency Ranking